AC
ACAD icon

Allstate Corporation’s Acadia Pharmaceuticals ACAD Stock Holding History

Allstate Corporation’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
23,755
-8,826
-27% -$194K 0.01% 958
2026
Q1 		$725K Buy
+32,581
New +$779K 0.01% 911

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Allstate Corporation's ACAD Position: Q2 2026 in Review

Allstate Corporation reduced its Acadia Pharmaceuticals (ACAD) stake by 27% in Q2 2026, selling an estimated $194K and leaving 23,755 shares worth $601K. The position accounts for 0.01% of the portfolio, ranked #958.

Allstate Corporation first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. The position peaked at $725K in Q1 2026. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Allstate Corporation held 23,755 shares of Acadia Pharmaceuticals worth $601K as of Q2 2026.
  • Allstate Corporation sold 8,826 Acadia Pharmaceuticals shares in Q2 2026, an estimated $194K.
  • Acadia Pharmaceuticals made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #958 holding.
  • Allstate Corporation first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Allstate Corporation's Acadia Pharmaceuticals position peaked at $725K in Q1 2026.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.